UBS analyst Trung Huynh lowered the firm’s price target on Bristol Myers to $43 from $47 and keeps a Neutral rating on the shares as part of a Q2 earnings preview for the U.S. pharmaceuticals group. For Q2, the firm is broadly in line with consensus on revenues “with a mixed performance from growth drivers.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target lowered to $41 from $43 at Barclays
- VYNE Therapeutics announces appointment of Banerjee as SVP
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 1, 2024
- 2seventy Bio announces sale of Hemophilia A candidate for up to $40M
- Bristol Myers Squibb call volume above normal and directionally bullish